Back
IMC
Immuron Limited
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual capital growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
1
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Immuron Ltd. engages in the research and development of oral immunotherapy, which focuses on bovine-colostrum with antibodies of choice for the treatment and prevention of a range of infectious and immune modulated diseases. The company is headquartered in Melbourne, Victoria and currently employs 5 full-time employees. The firm operates through two segments: Research and development (R&D) and Hyperimmune product. R&D segment focuses on R&D projects performed in Australia, Israel, and United States. Hyperimmune product segment is engaged in Travelan and Protectyn activities, which occurs in Australia, the Unites States and Canada. Its flagship products include Travelan and Protectyn. Travelan is a licensed natural health product and is indicated to reduce the risk of Travellers’ Diarrhea. Travelan is an over the counter immune supplement that can be taken to reduce the risk of diarrhea and reduce the symptoms of minor gastrointestinal disorders. Protectyn product helps to promote digestion and healthy gastrointestinal system health; support and maintain healthy liver function, and enhance immune defenses.
📈 Performance
Price History
+62.67%
1M
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.08
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in IMC
1
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in IMC
825 days
IMC investor breakdown
💵 Income of investors
More than 200k
50%
150k - 200k
50%
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
100%
🙋 Legal gender of investors
Female
Male
100%
Pearlers who invest in IMC also invest in...
MOAT.AX was created on 2015-06-26 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. The VanEck Morningstar Wide Moat ETF seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Morningstar Wide Moat Focus Index.
📊 Share price
$117.00 AUD
NULL GLOBAL
NULL SMART BETA
NULL THEMATIC
Appen Ltd. engages in the development of human-annotated datasets for machine learning and artificial intelligence. The company is headquartered in Chatswood, New South Wales and currently employs 1,475 full-time employees. The company went IPO on 2015-01-07. The firm is engaged in provision of data solutions and services for machine learning and artificial intelligence (AI). The firm operates through two segments: Global Services and New Markets. Global Services represents the services that the Company provides to its five United States technology customers (Global customers) using the customer's data annotation platforms and tools. New Markets comprises the Appen's data annotation platform and tools (Global Product), and the enterprise, government, and China business units. New Markets also includes Quadrant geolocation and Point-of-Interest (POI) data capabilities. Its Annotation Platform is the platform that both customers and internal teams use to design, run and manage data annotation tasks. The firm serves various industries including technology, automotive, financial services, healthcare, retail, and government agencies.
📊 Share price
$2.71 AUD
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. The company is headquartered in Melbourne, Victoria and currently employs 77 full-time employees. The company went IPO on 2004-12-16. The Company’s Remestemcel-L is mesenchymal lineage stromal cell product platform and is in late-stage development for treatment of systemic inflammatory diseases, including Pediatric steroid refractory acute Graft versus Host Disease (SR-aGVHD), acute respiratory distress syndrome (ARDS) and Biologic refractory inflammatory bowel disease. Its Rexlemestrocel-L is mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of advanced chronic heart failure (CHF) and chronic low back pain (CLBP) due to degenerative disc disease. Two products are commercialized in Japan and Europe by the Company’s licensees, and it has a commercial partnership in Europe and China for certain Phase III assets.
📊 Share price
$1.07 AUD
GOAT.AX was created on 2020-09-08 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. Each Fund aims to provide investment returns before fees and other costs which track the performance of the Reference Index in Australian dollars. Each Fund does not aim to perfectly replicate the Reference Index on a one-to-one basis.
📊 Share price
$25.66 AUD
NULL GLOBAL
NULL SMART BETA
NULL THEMATIC
NULL EX AUSTRALIA
Want more shares? Try these...
